Saltar al contenido
Merck

Emerging therapies in rosacea.

Journal of the American Academy of Dermatology (2013-11-28)
Alison Layton, Diane Thiboutot
RESUMEN

Rosacea is a common skin disorder with multiple symptoms. The emergence of research that furthers understanding of pathophysiological mechanisms has created new targets for disease treatment. Specifically, there is a need for new treatments that address the various erythematic symptoms associated with rosacea. Systemic and topical therapies have both yielded positive results in treating rosacea with various medications. Subantimicrobial-dose doxycycline is one such promising treatment. Development of novel products in the near future should help achieve more satisfactory outcomes for patients.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Doxiciclina hyclate
Sigma-Aldrich
Ivermectin
Supelco
Permethrin, PESTANAL®, analytical standard
Supelco
Doxiciclina hyclate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Doxycycline monohydrate
Ivermectin, European Pharmacopoeia (EP) Reference Standard
Supelco
Doxiciclina hyclate, VETRANAL®, analytical standard